These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14695001)

  • 1. Considerations in darbepoetin alfa cost and reimbursement: a model for pharmacy managers.
    Anderson ER; Gibson G
    Pharmacotherapy; 2003 Dec; 23(12 Pt 2):119S-124S. PubMed ID: 14695001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Lefebvre P; Vekeman F; Cremieux PY
    Ann Pharmacother; 2010 Mar; 44(3):595; author reply 595-6. PubMed ID: 20179253
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Morreale A; Plowman B; DeLattre M; Boggie D; Schaefer M
    Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.
    Vekeman F; McKenzie RS; Lefebvre P; Watson SH; Mody SH; Piech CT; Duh MS
    Am J Health Syst Pharm; 2007 Sep; 64(18):1943-9. PubMed ID: 17823106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting.
    Kruep EJ; Basskin LE
    Am J Health Syst Pharm; 2005 Dec; 62(24):2597-603. PubMed ID: 16333057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimbursement for erythropoiesis-stimulating agents poses challenges.
    Traynor K
    Am J Health Syst Pharm; 2008 Mar; 65(5):385-6. PubMed ID: 18281727
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic interchange of darbepoetin alfa for epoetin alfa in a multiinstitution health care system.
    Adamson R; Lew I; Allen P; Misuro A; Malacrida P
    Am J Health Syst Pharm; 2005 Nov; 62(22):2416-9. PubMed ID: 16278336
    [No Abstract]   [Full Text] [Related]  

  • 12. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing darbepoetin alfa continued.
    Deray G
    Am J Kidney Dis; 2003 Jun; 41(6):1334; author reply 1334-5. PubMed ID: 12776288
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Einarson T; Machado M; Walker J; Iskedjian M
    Curr Med Res Opin; 2007 Jul; 23(7):1571-3; author reply 1573-4. PubMed ID: 17637205
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.
    Barnett AL; Crémieux PY
    Pharmacotherapy; 2003 May; 23(5):690-3; discussion 693-4. PubMed ID: 12741447
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietic therapy: cost efficiency and reimbursement.
    Jaspan D
    Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S19-29. PubMed ID: 17687067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V; Knopf KB; Norris LB; Chen B; Yang YT; Qureshi ZP; Hrushesky W; Lebby AA; Schooley B; Hikmet N; Dickson M; Thamer M; Cotter D; Yarnold PR; Bennett CL
    J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.